113results about How to "Prevent and treat hyperlipidemia" patented technology

The invention discloses konjac jelly powder. The konjac jelly powder comprises the following components in part by weight: 30 to 40 parts of konjac powder, 10 to 25 parts of carrageenin, 0 to 10 parts of xanthan gum, 0 to 15 parts of locust bean gum, 0 to 20 parts of guar gum, 5 to 12.5 parts of sodium citrate, 8 to 15 parts of potassium chloride, 0 to 7 parts of xylitol and 2 to 5 parts of citric acid. A method for preparing jellies by using the konjac jelly powder comprises the following steps of: mixing the konjac jelly powder and white granulated sugar uniformly; pouring the mixed white granulated sugar and konjac jelly powder into a stirred cold water proportioning cylinder; continuously adding the white granulated sugar or syrup, opening steam and heating; and performing filtration, packing and sterilization to obtain konjac jelly finished products. The konjac jelly powder provided by the invention has low production cost, adjustable taste and high dietary fiber content; the prepared konjac jellies do not need to be treated by alkali; and the method for preparing the jellies by using the konjac jelly powder has simple making process and low making cost.

The invention relates to a sugar-free konjac soft sweet which comprises the following components in percentage by weight: 0.5-4% of konjac powder, 3-10% of gelatin, 15-25% of xylitol, 30-50% of isomalt, 3-8% of sorbitol, 2-5% of maltitol, 0.15-2% of acidity regulator, 0-0.5% of edible flavorant, 0-0.01% of edible colorant and 10-20% of water. The preparation method of the sugar-free konjac soft sweet comprises the following steps of: (1) preparing a glue solution; (2) preparing syrup; (3) preparing a mixed material solution; (4) forming the soft sweet; (5) setting and drying the soft sweet; and (6) obtaining the finished product. The sugar-free konjac soft sweet provided by the invention has high dietary fiber content, can provide abundant dietary fibers to human bodies, has low calories, can not decay teeth and is beneficial to body health. The invention also provides the preparation method of the sugar-free konjac soft sweet, which has a simple process and a low manufacturing cost.

The invention discloses a compound probiotic agent for improving immunity of dogs and reducing incidence of diarrhea as well as a preparation method and application thereof, and belongs to the field of the compound probiotic agent. The compound probiotic agent is prepared by mixing and compounding a lactobacillus plantarum KT-Lp9 microbial agent, a lactobacillus casei zhang microbial agent, a lactobacillus plantarum P-8 microbial agent, a bifidobacterium animalis subsp. lactis V9 microbial agent and a dilution carrier, wherein the quantity of viable bacteria of the four kinds of microbial agents is more than or equal to 2*10<11>CFU/g. The compound probiotic agent with different contents of viable bacteria only can be applied to 96 dogs at different ages for 60 days, so that the immunity of the test dogs can be improved, and the incidence of diarrhea and the sickness degree are reduced. Main representations are that the feed intake and growth rate of the dogs are increased, leukocyte counts, lymphocytes counts and neutrophil counts in blood are controlled, and the contents of four immunologic factors including immune globulin G, interleukin 6, interferon alpha and tumor necrosis factor alpha in the blood can be increased; and meanwhile, the content of secretory immunoglobulin A (SigA) in excrement is increased.

A tea oil for preventing hypertension, hyperlipomia, coronary heart disease and habitual constipation is prepared from useless tea leaves and tea seeds through baking, squeezing to obtain raw oil and cake, refining the raw oil, immersion extracting of cake to obtain oil, and refining. Its advantages are simple process, low cost and high productivity.

The invention relates to the use of pepper amide compound in preparation of drug or healthcare product for reducing blood fat with the general formula (I), wherein R, R1, R2 are defined in the specification, the piperamide compounds represented by formula (1) have the actions of substantially reducing cholesterin, triglyceride and increasing high density lipoprotein, fully activating lecithin cholesterol acyl transferase, forwarding extra-hepatic tissue cholesterol to liver, cleaning out plasma lipoproteins, plasma cholesterol and cholesterol esters, thus can be applied to the prevention and treatment of cardiovascular and cerebrovascular diseases, such as atherosclerotic, cerebrovascular, coronary artery and peribiliary vessel pathology and hyperlipemia.

The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I):

wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X₁, X₂, X₃, and X₄ may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO₂—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.

The invention relates to the use of piperic acid ester compound in preparation of drug or healthcare product for reducing blood fat, wherein R1, R2, R3 are defined in the description, the piperic acid ester compounds represented by formula (1) have the actions of substantially reducing cholesterin, triglyceride and increasing high density lipoprotein, fully activating lecithin cholesterol acyl transferase, forwarding extra-hepatic tissue cholesterol to liver, cleaning out plasma lipoproteins, plasma cholesterol and cholesterol esters, thus can be applied to the prevention and treatment of cardiovascular and cerebrovascular diseases, cerebrovascular, coronary artery and peribiliary vessel pathology and hyperlipemia.

The invention relates to a novel compound propolis preparation and a preparation method thereof. The compound propolis product is prepared form the following ingredients: supercritical propolis, supercritical perilla frutescens seed oil, supercritical glossy ganoderma spore oil and ethanol extracted supercritical propolis residue. A main technical method has the following steps: removing impurities from raw materials; pulverizing raw materials; carrying out CO2 supercritical extraction; preparing microcapsule emulsion; carrying out vacuum freeze drying; carrying out pulverization; stirring and mixing all ingredients; and carrying out sterilization, capsule filling and package. The product of the invention belongs to the health care food with higher nutritional value, and has various health care effects of blood pressure reduction, blood fat reduction, antioxidation, immunity improvement and the like.

A Chinese medicine in the form of oral liquid or others for preventing diabetes and its complication, hyperlipemia, hypertension, retinosis and cardiovascular disease is prepared from 9 Chinese-medicinal materials including ginseng, wolfberry fruit, red sage root, pueraria root, etc. Its preparing process is also disclosed.

The invention discloses a citrus chachiensis hortorum polymethoxylated flavonoids effective part and application thereof for treating hyperlipidaemia. The effective part is prepared from the following steps: step S1, extracting: grinding the citrus chachiensis hortorum, extracting by use of an alcohol-water solution, concentrating; step S2, removing impurities; sampling the concentrated solution obtained in the step S1 on macroporous resin, eluting and removing impurities by use of an ethanol water solution with the volume percent concentration of 40-45%, wherein the model of the macroporous resin is D101 type; and step S3, eluting: eluting the macroporous resin by use of the ethanol water solution with the volume percent concentration of 90% or more, collecting eluent, concentrating to obtain the citrus chachiensis hortorum polymethoxylated flavonoids effective part. The citrus chachiensis hortorum polymethoxylated flavonoids effective part provided by the invention can effectively lower the blood lipid level of hyperlipidaemia model mice, and is non-toxic, safe and effective, and can be used for preventing or treating hyperlipidaemia.

The invention discloses health tea capable of reducing high blood pressure, high blood sugar and high blood fat and relates to the technical field of traditional Chinese medicines. The health tea is prepared from the following raw materials in percentage by weight: 35-55% of momordica grosvenori flower, 10-30% of herba abri, 3-8% of gynostemma pentaphylla, 6-15% of prunella vulgaris, 3-8% of folium mori, 3-8% of parasitic loranthus, 3-8% of pueraria lobata, 1-4% of uncaria rhynchophylla, 1-4% of herba epimedii and 1-4% of stigma maydis. The health tea is remarkable in reducing and preventing high blood pressure, high blood sugar and high blood fat, free of toxic or side effect, convenient to dissolve, particularly suitable for being drunk daily, and used for treating and preventing high blood pressure, high blood sugar and high blood fat.

A medicine for supplementing Ca, Mg and VD to human body is proportionally prepared from Ca preparation, Mg preparation and VD.

The invention discloses a Chinese medicine used for the prevention and treatment of atherosclerosis and coronary heart disease, and a preparation method thereof. The Chinese medicine is prepared by bulk drugs with following weight percentages: 10 to 30 parts by weight of radix pseudoginseng, 10 to 30 parts by weight of ginkgo leaf, 10 to 30 parts by weight of radix salviae miltiorrhizae, 10 to 30 parts by weight of astragalus root, 10 to 30 parts by weight of radix puerariae, 10 to 20 parts by weight of semen cassiae, 10 to 20 parts by weight of radix paeoniae rubra, 10 to 20 parts by weight of rhizoma curcumae longae, 10 to 20 parts by weight of herba epimedii, 10 to 20 parts by weight of dwarf lilyturf root, 10 to 20 parts by weight of rehmanniae and 5 to 10 parts by weight of liquorice. With the effectiveness of activating blood circulation to dissipate blood stasis, benefiting vital energy to remove stagnation and promoting pulse to descend the turbid, the Chinese medicine of the invention can be used for preventing and treating atherosclerosis, hyperlipemia, coronary heart disease and angina, etc.

The invention discloses a traditional Chinese medicine containing pseudo-ginseng powder and a preparation method thereof. The traditional Chinese medicine comprises, by mass, 60-100 parts of pseudo-ginseng powder, 20-30 parts of red sage root, 10-20 parts of licorice, 30-40 parts of radix rehmanniae, 15-25 parts of root of kudzu vine, 40-50 parts of radix astragali, 20-30 parts of bighead atractylodes rhizome, 60-80 parts of dextrin and 5-7 parts of powdered steatile. The traditional Chinese medicine utilizes pseudo-ginseng powder, red sage root and licorice as raw materials, does not contain hormones and antibiotics in Western medicines, and does not produce drug resistance. Natural plants adopted by the preparation method has no obvious toxic or side effects in research, have high safety, can be absorbed easily, can produce effects fast and are convenient for use. The traditional Chinese medicine can treat inner and outer hemorrhagic diseases such as a bleeding wound, blood stasis, gastrorrhagia and hematuria, has effects of expanding blood vessel, dissolving thrombus, improving microcirculation, preventing and treating cardiovascular and cerebrovascular diseases such as hyperlipidemia, cholesterol increasing, coronary heart disease, stenocardia and cerebral hemorrhage sequel, treating liver diseases such as fatty liver and liver fibrosis, and treating physical deficiency caused by hemorrhage, delivery and aeipathia, has a low cost and simple processes, and can be widely used.

The invention discloses a houttuynia cordata thunb beverage belonging to the food field. The production method thereof is as follows: (1) fresh houttuynia cordata thunb is juiced by being added with 2-3 times of water, and tea leaves are added with 2-3 times of water for soaking or the fresh houttuynia cordata thunb is crushed into 300 to 1000 items and then added with 4-5 times of water; (2) 10 to 20 percent of houttuynia cordata thunb juice, 10 to 20 percent of tea, 1 to 5 percent of citric acid, 5 to 9 percent of sugar and the balance of 50 to 60 percent of water are mixed, evenly stirred, filtered and then packed, thus obtaining the beverage. The beverage has better mouthfeel, can accelerate gastrointestinal absorption and effectively protect lung cells, prevent and cure hyperlipoidemia and cerebral apoplexy, and has the functions of cellular oxidation inhibiting and anti-aging and health care.

The invention discloses application of polyoxymethylflavone, a polyoxymethylflavone composition and a polyoxymethylflavone preparation for prevention or treatment of hyperlipidemia. The active ingredient of a drug for the prevention or treatment of the hyperlipidemia comprises polyoxymethylflavone, wherein the polyoxymethylflavone refers to 3,5,6,7,8,3',4'-heptamethoxyflavones, and the active ingredient further comprises pharmaceutically acceptable carriers or excipients so as to be prepared into a pharmaceutically acceptable dosage form. The high level of either of the total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-c) of plasma can cause the hyperlipidemia. The invention confirms that 3,5,6,7,8,3',4'-heptamethoxyflavones (HMF) can significantly reduce the levels of the TG, the TC and the LDL-c, significantly increase the level of HDL-C in the plasma, and prevent or treat the hyperlipidemia.

The invention relates to a preparation method and use of Xanthoceras sobifoba kernel oil extracted from supercritical fluid and a preparation of the Xanthoceras sobifoba kernel oil. The preparation method comprises the steps of grinding Xanthoceras sobifoba kernels, sieving by virtue of a 10-100-mesh sieve, and carrying out supercritical fluid extraction in an extraction kettle, so as to obtain the Xanthoceras sobifoba kernel oil and a kernel residue rich in proteins, wherein the kernel residue can be used for extracting total saponins and has an extremely high medical value. Compared with a traditional squeezing process, a CO2 supercritical fluid extraction method has the advantages that the process is simple, the production cycle is short, the extraction efficiency is high, and the serious damage of unsaturated fatty acid in grease and the denaturationof the proteins in medicine residues at the high temperature are avoided. Compared with a method for extracting by virtue of organic solvents such as petroleum ether, the CO2 supercritical fluid extraction method has the advantages that the residual solvent is avoided, operation condition are mild, and the production is safe, toxic free and environmentally friendly. The oil extraction rate of the Xanthoceras sobifoba kernels is not lower than 50%, and GC-MS detection shows that the content of unsaturated fatty acid reaches up to 75% or above. By adding medical auxiliary materials, the dose forms of soft capsules, micro-capsules, cyclodextrin coated preparations, dripping pills and the like can be prepared and can be used for developing health products for preventing and treating hypertension, hyperlipemia and diseases of cardiovascular systems.

A pharmaceutical composition useful for the prevention and/or treatment of hyperlipidemia, which comprises combining an effective amount of a squalene synthase inhibitor and a HMG-CoA reductase inhibitor is provided. Furthermore, a method for preventing and / or treating hepatic toxicity caused by the administration of a HM6-C0A veductase inhibitor, which comprisis adminisvering an effective amount of a sgualence synthase inhibitor, is provided .

A Chinese medicine for treating vascular dementia is prepared from ginseng, notoginseng and earthworm. Its preparing process is also disclosed.

The invention discloses an application of lactobacillus casei and ginkgo leaf extract in preparing medicines used for controlling hyperlipidemia. With a synergetic effect of lactobacillus casei and ginkgo leaf extract, obese mice body mass, TC, TG and MDA are substantially reduced. Degradation rates of TC and TG are respectively improved by 24.48% and 20.93%; mice weight is reduced by 13.22% than a high-fat group; and MDA content is reduced by 5.98%. In mice serum, HDL-C is substantially increased, wherein an increasing rate reaches 167.85%. GSH-PX in mice body is increased by 13.14%. Activities of enzymes such as CAT and SOD are respectively reduced by 49.02% and 3.13%. With the synergetic effect of lactobacillus casei and ginkgo leaf extract, functions of blood fat reducing, cholesterol metabolism promoting, and weight controlling are provided. Therefore, lactobacillus casei and ginkgo leaf extract can be used in preventing and treating hyperlipidemia.